Rimonabant

Radioligand Binding Assay

Human CB1 and CB2 stably transfect HEK 293 cells and cell membrane is purified. 0.2-8 μg of the purified membrane is incubated with 0.75 nM [3H] CP55,940 and Rimonabant in the incubation buffer (50 mM Tris-HCl, 5 mM MgCl2, 1 mM EDTA, 0.3%BSA, pH 7.4). The non-specific binding is defined in the presence of 1 μM of CP55,940. The reactions are incubated for one and a half hours at 30 °C in Multiscreen. The reactions are terminated by manifold filtration and washed four times with ice-cold wash buffer (50mM Tris, pH 7.4, 0.25% BSA).The radioactivity bound to the filters is measured by Topcount. The IC50 is determined as the concentration of Rimonabant required to inhibit 50% of the binding of [3H] CP55,940 and calculated by non-linear regression.

Cell lines

Peripheral blood mononuclear cells (PBMC); keratinocyte cell line (C5N cells)

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

Patients received rimonabant 20 mg daily, for 4 weeks; or 0.3–10 μM for 24 h and 48 h

Applications

Treatment with rimonabant in peripheral blood mononuclear cells (PBMC) did not induce significant changes of monocytes, B cells, total T cells or T cell subsets. Moreover, there was a small but significant increase in CD16+, CD3–, and/or CD56+ cells after rimonabant therapy. Additionally, Rimonabant reduced keratinocyte cell line (C5N cells) viability by induction of apoptosis.

Animal models

Male CD-1 mice model

Dosage form

0.1,0.3, and 1.0μmol·cm-2 for 6 h or 24 h

Applications

Rimonabant significantly reduced oedema and leukocyte infiltrate, and showed topical anti-inflammatory activity in mice.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

1. Chu, C. M., Hung, M. S., Hsieh, M. T., Kuo, C. W., Suja, T. D., Song, J. S., Chiu, H. H., Chao, Y. S. and Shia, K. S. (2008) Bioisosteric replacement of the pyrazole 3-carboxamide moiety of rimonabant. A novel series of oxadiazoles as CB1 cannabinoid receptor antagonists. Org Biomol Chem. 6, 3399-3407

2. Malfitano, A. M., Sosa, S., Laezza, C., De Bortoli, M., Tubaro, A. and Bifulco, M. (2011) Rimonabant reduces keratinocyte viability by induction of apoptosis and exerts topical anti-inflammatory activity in mice. Br J Pharmacol. 162, 84-93

3. Almestrand, S., Wang, X., Jeppsson-Ahlberg, A., Nordgren, M., Flygare, J., Christensson, B., Rossner, S. and Sander, B. (2015) Influence of rimonabant treatment on peripheral blood mononuclear cells; flow cytometry analysis and gene expression profiling. PeerJ. 3, e1056